Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697223 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
A Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06697223 is a Phase 2 study of Healthy Subjects that has completed, run by Cerus Corporation. The registered enrollment target is 40 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06697223, a Phase 2 study of Healthy Subjects, has completed, sponsored by Cerus Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection. The post-infusion recovery and survival of autologous radiolabeled 5-day INTERCEPT platelets (Test) stored in 100% plasma will be measured in comparison to fresh autologous radiolabeled platelets (Control).
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for Platelets with LED Illuminator
Study Locations (2)
Virginia
- American Red Cross Research Laboratory - Norfolk
Washington
- Bloodworks Northwest Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06697223
The ClinicalTrials.gov registry entry for NCT06697223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (69% lower). The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which INTERCEPT Blood System for Platelets with LED Illuminator is the first listed.
NCT06697223 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Virginia, Washington.
Frequently Asked Questions
What is clinical trial NCT06697223 about?
NCT06697223 is a clinical study titled "A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.". The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection. The post-infusion recovery and survival of autologous radiolabeled 5-d...
What is the current status of trial NCT06697223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-01-23. Estimated completion is 2025-06-13.
What conditions does trial NCT06697223 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT06697223?
The interventions under investigation include: INTERCEPT Blood System for Platelets with LED Illuminator (DEVICE).
Who is sponsoring clinical trial NCT06697223?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697223 being conducted?
This trial has 2 study locations across Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
RECRUITING · Phase 2
-
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
COMPLETED · Phase 2
-
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
RECRUITING
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Radiocaine Safety Study In Healthy Human Subjects
RECRUITING · Early Phase 1
-
Optimizing Ultrasound-induced Anti-inflammation in Human Subjects
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.